Chimerix (STU:CXF) ROCE % : -66.63% (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Chimerix ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Chimerix's annualized ROCE % for the quarter that ended in Sep. 2024 was -66.63%.

Chimerix ROCE % Historical Data

The historical data trend for Chimerix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix ROCE % Chart

Chimerix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-35.90

-45.24

-128.01

-37.14

-40.39

Chimerix Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-49.41	-40.74	-52.91	-55.38	-66.63

Chimerix ROCE % Calculation

Chimerix's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-85.341	/	( ( (263.698 - 19.272)	+	(195.114 - 16.912) )	/ 2 )
	=	-85.341	/	( (244.426	+	178.202)	/ 2 )
	=	-85.341	/	211.314
	=	-40.39 %

Chimerix's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-89.352	/	( ( (165.837 - 20.533)	+	(142.96 - 20.042) )	/ 2 )
	=	-89.352	/	( ( 145.304	+	122.918 )	/ 2 )
	=	-89.352	/	134.111
	=	-66.63 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Chimerix (STU:CXF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Chimerix ROCE % Related Terms

Thank you for viewing the detailed overview of Chimerix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimerix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (STU:CXF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CMRX:USA

Address

2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713

Website

https://www.chimerix.com

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Chimerix Headlines

No Headlines